Novavax signs agreement with European Commission for COVID19 vaccine

Deal for 100 million doses with additional 100 million through 2023

Biocon Biologics and Viatris receive European Commission approval for Kixelle, Biosimilar Insulin Aspart

The centralized marketing authorization granted by the EC is valid in all EU Member

Biocon Biologics signs settlement and lcense agreement to commercialize biosimilar Aflibercept

All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed

EMA backs higher-dose Wegovy, clearing path for greater weight loss option in Europe

EMA backs Eylea 8 mg for retinal vein occlusion

The positive CHMP opinion is supported by results from the Phase III QUASAR trial

Merck wins key EU backing to expand use of PAH Drug WINREVAIR

WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states

Roche secures European nod for Gazyva/Gazyvaro in Lupus Nephritis patients

The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies

DBT, BIRAC and CEPI renew cooperation agreement for vaccine development

DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential

Celltrion gets Health Canada nod for Eylea biosimilar Eydenzelt

Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data

EIB, Angelini Ventures team up to pump €150 million into European biotech, digital health startups

Angelini Ventures has already invested €125 million in 22 startups